Market research
VBLT Vascular Biogenics Ltd
NASDAQ USD Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 12M
- P/E ratio
- Not available
- Analyst target
- 5
- Dividend yield
- 0.0%
- Beta
- 0.71
Community
Investor discussion
1 comment
Sign in to join the VBLT discussion.
5 years, 4 months ago
Vascular Biogenics Ltd is currently in a long term uptrend where the price is trading 13.4% above its 200 day moving average.
From a valuation standpoint, the stock is 92.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 102.8.
Vascular Biogenics Ltd's total revenue rose by 62.7% to $205K since the same quarter in the previous year.
Its net income has dropped by 26.7% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 96.2% to $-7M since the same quarter in the previous year.
Based on the above factors, Vascular Biogenics Ltd gets an overall score of 3/5.